Credit: A vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London Wednesday, Oct. 7, 2020. Novavax Inc. said Thursday Jan. 28, 2021 that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well — against new mutated strains of the virus circulating in that country and South Africa. (AP Photo/Alastair Grant)
COVID vaccine from Md.-based Novavax gets preliminary approval in the UK
